

# Oculomotor Nerve Neuromyotonia

## An Inflammatory Syndrome


Adam Handel, BMBCh, MA, DPhil, MRCP, Sarosh R. Irani, BMBCh, MA, DPhil, FRCP, and Ashwini Oswal, MBBS, MA, DPhil, MRCP

*Neurology*® 2024;103:e209769. doi:10.1212/WNL.0000000000209769

### Correspondence

Dr. Oswal  
ashwini.oswal@ndcn.ox.ac.uk

### Figure MRI Imaging Findings



(A) Axial T1 postcontrast MRI demonstrating smooth enhancement of the cisternal portion of the left oculomotor nerve. (A) CSF filled dural cuff surrounds the nerve, which is susceptible to inflammatory, compressive, or neoplastic pathology.<sup>2</sup> (B) The 3D constructive interference in steady state sequence is useful for visualizing abnormal signal within the nerve (red arrow).

A 68-year-old woman presented with a 1-year history of episodic, painless double vision. On examination, diplopia was triggered by sustained right lateral gaze. On subsequent return to neural gaze, the left eye remained 'locked' in adduction (Video 1). Impairments of abduction and vertical movements of the left eye were noted, consistent with a diagnosis of left oculomotor nerve neuromyotonia.<sup>1</sup>

MRI revealed smooth enhancement of the left oculomotor nerve (Figure), which was unchanged on repeat scanning after 6 months but had resolved after 1 year. Investigations did not reveal a causative pathology, and the patient's symptoms resolved with carbamazepine. An inflammatory process was thought most likely based on the spontaneous resolution of the enhancement pattern.

Ocular neuromyotonia is a rare condition causing transient diplopia due to extraocular muscle spasm, often secondary to ephaptic transmission in a damaged ocular motor nerve. Common causes include cranial irradiation, but many cases are idiopathic.<sup>1</sup>

## Disclosure

A. Oswal has received research support from an MRC Clinician Scientist Fellowship (MR/W024810/1). A. Handel has received funding from the MRC (MR/X022013/1) and UCB

### MORE ONLINE

 Video

From the Nuffield Department of Clinical Neurosciences (A.H., A.O.), University of Oxford, United Kingdom; and Department of Neurology (S.R.I.), Mayo Clinic, Jacksonville, FL. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

e209769(1)

Pharma. S.R. Irani has received honoraria/research support from UCB, BioHaven therapeutics, Immunovant, MedImmune, Roche, Janssen, Cerebral therapeutics, ADC therapeutics, Brain, CSL Behring, and ONO Pharma, receives licensed royalties on patent application WO/2010/046716 entitled “Neurological Autoimmune Disorders,” has filed 2 other patents entitled “Diagnostic method and therapy” (WO2019211633 and US app 17/051,930; PCT application WO202189788A1) and “Biomarkers” (WO202189788A1, US App 18/279,624; PCT/GB2022/050614), and has received research support from an MRC Senior Clinical Fellowship (MR/V007173/1), a Wellcome Trust Fellowship (104079/Z/14/Z), and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC).

## Author Contributions

A. Handel: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. S.R. Irani: drafting/revision of the

manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. A. Oswal: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data.

## Study Funding

The authors report no targeted funding.

## Publication History

Received by *Neurology* May 31, 2024. Accepted in final form June 13, 2024. Submitted and externally peer reviewed. The handling editor was Editor-in-Chief José Merino, MD, MPhil, FAAN.

## References

1. Soares-Dos-Reis R, Martins AI, Brás A, Matos A, Bento C, Lemos J. Ocular neuromyotonia. *Pract Neurol*. 2018;18(5):389-390. doi:10.1136/practneurol-2017-001866
2. Mark AS, Blake P, Atlas SW, Ross M, Brown D, Kolsky M. Gd-DTPA enhancement of the cisternal portion of the oculomotor nerve on MR imaging. *AJNR Am J Neuroradiol* 1992;13(5):1463-1470.



The *Neurology*® Diversity, Equity, & Inclusion (DEI) online section provides a welcoming, respectful, and safe environment for the neurology community to amplify perspectives and lived experiences, and to share opportunities that advance DEI. Visit the site at: [Neurology.org/dei](https://www.neurology.org/dei)



Join us to learn from experts as they discuss recently published *Neurology* journal articles and hot topics in the field of neurology. Articles and discussants are selected by the editors of *Neurology*.

### Topics include:

- Myasthenia Gravis/ALS/Neuromuscular
- Cognitive Disorders
- Epilepsy
- Headache/Migraine
- Parkinson Disease/Movement Disorders
- Stroke
- Multiple Sclerosis

Start watching now at: [Neurology.org/video-journal-club](https://www.neurology.org/video-journal-club)